The PGM2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of human Raji B lymphocytes with disrupted PGM2 (phosphoglucomutase 2). This heterogeneous pool, generated without clonal isolation, provides a loss-of-function model free of clonal artifacts. The polyclonal format allows phenotype assessment across a diverse genetic background, suitable for gene function studies in a near-native context. This product enables dissection of PGM2??s role in carbohydrate metabolism within a lymphoblastoid environment, supporting high-throughput screening and functional genomics.
The Raji host cell line is an EBV-positive Burkitt lymphoma-derived B lymphocyte that grows in suspension with lymphoblastoid morphology. Raji cells are widely used in immunology and oncology due to their native roles in antibody production, immune response, and antigen presentation. Their rapid proliferation and ease of culture ensure reproducible workflows. The Burkitt lymphoma origin makes them valuable for studying metabolic dependencies and oncogenic signaling in aggressive B cell malignancies.
PGM2 catalyzes the reversible conversion of glucose-1-phosphate to glucose-6-phosphate, a key step in glycogen metabolism and galactose utilization. This positions PGM2 at a metabolic intersection, with its product glucose-6-phosphate entering glycolysis and the pentose phosphate pathway, and its substrate glucose-1-phosphate serving as a precursor for UDP-glucose, critical for glycogen synthesis and glycosylation. Interacting factors include glycogen metabolic enzymes, glycogenin, and UDP-glucose pyrophosphorylase. Downstream targets comprise glucose-6-phosphate, UDP-glucose, glycolytic intermediates, and pentose phosphate pathway metabolites. Upstream regulation is not fully characterized but may involve nutrient and hormonal cues. Representative pathway components include PGM1, glucose-1-phosphate, glucose-6-phosphate, UDP-glucose, glycogen synthase, and hexokinase.
In Raji B lymphocytes, PGM2 disruption is expected to perturb central carbon metabolism by altering glucose-1-phosphate/glucose-6-phosphate balance, impairing glycogen turnover and reducing nucleotide sugar flux for glycosylation. This can compromise B cell receptor function, antibody secretion, and immune synapse formation. Metabolic rewiring may also affect glycolysis and the pentose phosphate pathway, altering redox balance and precursor supply. Given the Burkitt lymphoma origin, this model is particularly relevant for studying metabolic disruptions in oncogenic signaling and cancer survival, and offers insights into phosphoglucomutase deficiency-related disorders.
The PGM2 Knockout Raji Polyclonal Cells are suited for glycogen and galactose pathway analysis, cancer metabolic reprogramming studies, and glycosylation investigation. Researchers can employ western blotting and RT-qPCR to confirm PGM2 loss, measure glucose-6-phosphate and glycogen content for functional validation, and perform metabolic flux analysis to trace carbon redistribution. Cell viability assays under varied nutrient conditions can evaluate drug sensitivity. This model also supports co-culture experiments for immune interactions and antigen presentation under altered carbohydrate metabolism. For assistance, contact Ascent Research.
